Ivantis gets $27M boost for trials of microstent in eye patients

02/4/2013 | Healio

A round of Series B financing led by Ascension Health Ventures has brought in $27 million for Ivantis. The company will use the money to conduct four global clinical studies of its Hydrus microstent, a tiny device that assists in restoring a glaucoma patient's natural eye outflow pathway.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX